1COHN J N.Structural basis for heart failure.Ventricular remodeling and its pharmacolo gical inhibition[J].Circulation,1995,91(10):2504-2507.
2KANTOR P F,LUCIEN A,KOZAK R,et al.The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase[J].Circ Res,2000,86(5):580-588.
3STANLEY W C,MARIILLI M.Metabolic therapy in the treatment of ischaemic heart disease:the pharmacology of trimetazidine[J].Fundam Clin Pharmacol,2003,17(2):133-145.
4BELARDINELLI R,PURCARO A.Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy[J].Eur Heart J,2001,22(23):2146-2170.
5MADAMANCHI N R,VENDROV A,RUNGE M S.Oxidative stress and vascular disease[J].Arterioscler Thromb Vase Biol,2005,25(1):29-38.
6FAADIEL ESSOP M,OPIE L H.Metabolic therapy for heart failure[J].Eur Heart J,2004,25(20):1765-1768.
